Gilead Sciences stock has moved higher after the biopharma group reported a narrower adjusted loss f

HighTower Advisors LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,534,627 shares of the biopharmaceutical c

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,032,295 shares of the biophar

Amundi cut its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,772,438 shares of the biopharmaceutical company

Saudi Central Bank lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 89.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 86,886 shares of the biopharmaceutical company

Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.

Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out. Here is what that risk actually means for income investors counting on the check.

NEOS Investment Management LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 950,430 shares of the biopharmaceutical company

TD Waterhouse Canada Inc. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 12.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 482,201 shares of the biopharmaceutical

AXQ Capital LP acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 27,106 shares of the biopharmaceutical company